Treatment of head and neck squamous cell carcinoma cells (HNSCC) with Cetuximab, an EGFR-blocking monoclonal antibody, resulted in downregulation of HIF-1α, which decreased the expression of LDHA [41], and in patient-derived HNSCC xenografts Cetuximab treatment decreased lactate labeling from hyperpolarized [1-13C]pyruvate [42]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.